Sharp Rx price jumps way up, says GAO

Share this article:

A Government Accountability Office study found “extraordinary price increases” in 416 branded drug products (across 321 brands) between 2000 and 2008. That's about half of one percent of all branded drug products.

The term “branded drug products” encompasses different drug strengths and dosage forms of the same drug brands, and GAO defines “extraordinary price increases” as those of more than 100% at a single point in time.

The number of extraordinary price increases per year has more than doubled from 2000 to 2008, the GAO said, with most of those price increases ranging between 100% and 499%. The higher prices were sustained on nearly 90% of those products, with some seeing further price increases. More than half of those products were in three therapeutic classes – CNS, anti-infective and cardiovascular.

The report, prepared for Sens. Charles Schumer (D-NY) and Amy Klobuchar (D-MN), ascribed the increases to limited competition and a lack of therapeutically equivalent drugs due to patent protection and market exclusivity. The recent wave of corporate consolidations, the GAO said, may be further fueling the trend by reducing competition between branded drugs fielded by different companies.

The GAO's findings were based on changes in average wholesale price based on data from Thomson Reuters' Red Book.  

PhRMA took issue with the GAO's methodology, questioning the use of average wholesale price as representing not manufacturer prices but those of distributors. The trade group pointed to a sharp decline in retail prescription drug spending growth to make the case for drugs as one of the more cost-effective segments of healthcare spending.

“Pharmaceutical research companies make price adjustments independently as a result of market forces," said PhRMA SVP Ken Johnson, "which include everything from patent expirations to the huge, sunk R&D costs which typically exceed $1 billion for a single medicine, as well as the ability of powerful purchasers to obtain large savings, benefiting patients."

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...